CG Oncology, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. CG Oncology is a clinical-stage biopharmaceutical company developing cretostimogene for bladder cancer. It has no approved products and has not generated product-sales revenue.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Research and collaboration revenue | $0.5 million | $0.2 million |
| Research and development expense | $17.2 million | $7.8 million |
| General and administrative expense | $5.8 million | $2.1 million |
| Operating loss | $22.5 million | $9.7 million |
| Net loss | $16.9 million | $8.7 million |
| Net loss per share, basic and diluted | $0.36 | $3.22 |
| Net cash used in operating activities | $26.0 million | $8.0 million |
Interest income was $5.5 million, versus $1.0 million a year earlier, partly offsetting the operating loss. No product gross margin is reported because the company has no product sales. At March 31, cash and cash equivalents were $77.5 million and marketable securities were $489.0 million, totaling $566.5 million; reported working capital was $568.6 million. Total liabilities were $10.2 million. The company reported no outstanding term debt; it repaid the loan in May 2023 and paid a $0.4 million related success fee in March 2024.
Material changes and notable items
- R&D expense increased $9.4 million year over year, primarily from higher clinical-trial, CMC, and related third-party costs, as well as increased R&D headcount.
- G&A expense increased $3.7 million, mainly due to higher personnel, professional and consulting costs, and public-company-related expenses.
- Operating cash use rose to $26.0 million. Investing cash use of $307.4 million largely reflected purchases of marketable securities; financing provided $402.7 million, primarily from the IPO.
- The January 2024 IPO sold 23.0 million shares at $19 per share and generated approximately $399.6 million in net proceeds. Preferred shares converted to common stock in connection with the offering. The company reported 66.6 million common shares outstanding at quarter-end.
- Stock-based compensation expense was $1.5 million, compared with $0.2 million in Q1 2023.
Outlook, risks and contingencies
- Management estimates existing cash, cash equivalents and marketable securities will fund projected operating expenses and capital expenditures through 2027. This estimate depends on assumptions that may prove incorrect; the company has no other committed capital source and may require additional funding.
- Management expects expenses and operating losses to increase as clinical development advances. BOND-003, a Phase 3 trial of cretostimogene in high-risk BCG-unresponsive non-muscle invasive bladder cancer, had completed enrollment; the company reported interim data in May 2024 and expected topline data by year-end 2024. The filing says a successful trial could support a BLA submission. CORE-001 is evaluating combination treatment with pembrolizumab, and PIVOT-006 is a second Phase 3 trial in intermediate-risk patients.
- Development, regulatory approval, commercialization, and profitability remain uncertain. The company relies on third parties to manufacture and distribute cretostimogene, and expects continued clinical, regulatory, and manufacturing costs.
- ANI Pharmaceuticals sued on March 4, 2024, seeking a declaration that a 2010 agreement entitles it to royalties on certain cretostimogene net sales. CG Oncology disputes the allegations and intends to defend the matter; the filing does not provide a clear estimate of potential financial exposure.
- The company reported effective disclosure controls and no material changes to internal control over financial reporting during the quarter. It also reported no material changes to the risk factors in its 2023 Form 10-K.
Key facts for investors to verify
- Progress, safety and efficacy results, and timing of topline data for BOND-003 and other cretostimogene trials.
- Whether the stated runway through 2027 remains supportable as trial, manufacturing, and public-company costs develop.
- Potential royalty obligations or other consequences from the ANI litigation.
- Future funding needs, collaboration economics, and the impact of any additional equity issuance on shareholders.